08:00 , Dec 14, 2015 |  BC Week In Review  |  Company News

Amgen, Merck deal

The companies will evaluate AMG 820 from Amgen and cancer drug Keytruda pembrolizumab from Merck in an open-label Phase I/II trial to treat select advanced solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer...
02:09 , Dec 5, 2015 |  BC Extra  |  Company News

Amgen, Merck plan Blincyto-Keytruda combo study

Amgen Inc. (NASDAQ:AMGN) and Merck & Co. Inc. (NYSE:MRK) plan to launch two clinical studies next year evaluating cancer immunotherapy combination therapies including Merck's PD-1 inhibitor Keytruda pembrolizumab . Amgen will lead an open-label Phase...
07:00 , Oct 31, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115) Mouse studies suggest the brain-penetrant CSF1R inhibitor BLZ945 could be used to treat glioblastoma multiforme (GBM)....